Acuta Capital Partners LLC Has $7.57 Million Stock Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN)

Acuta Capital Partners LLC lowered its holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 25.5% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,368 shares of the company’s stock after selling 101,330 shares during the period. Enliven Therapeutics comprises about 6.1% of Acuta Capital Partners LLC’s portfolio, making the stock its 5th largest holding. Acuta Capital Partners LLC’s holdings in Enliven Therapeutics were worth $7,569,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Quest Partners LLC boosted its stake in shares of Enliven Therapeutics by 87.3% during the 2nd quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock worth $37,000 after buying an additional 742 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in shares of Enliven Therapeutics by 64.4% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,085 shares of the company’s stock worth $232,000 after purchasing an additional 3,559 shares during the last quarter. SG Americas Securities LLC bought a new stake in shares of Enliven Therapeutics during the 3rd quarter worth approximately $256,000. The Manufacturers Life Insurance Company acquired a new stake in shares of Enliven Therapeutics in the 2nd quarter valued at approximately $322,000. Finally, The Manufacturers Life Insurance Company boosted its holdings in shares of Enliven Therapeutics by 25.6% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 17,282 shares of the company’s stock valued at $441,000 after buying an additional 3,518 shares during the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 7,522 shares of the company’s stock in a transaction dated Friday, October 4th. The shares were sold at an average price of $27.51, for a total value of $206,930.22. Following the transaction, the insider now owns 1,069,887 shares in the company, valued at approximately $29,432,591.37. This represents a 0.70 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Benjamin Hohl sold 4,250 shares of the stock in a transaction dated Friday, September 27th. The shares were sold at an average price of $24.27, for a total transaction of $103,147.50. The disclosure for this sale can be found here. Insiders sold 123,945 shares of company stock valued at $3,451,099 in the last quarter. 29.20% of the stock is currently owned by insiders.

Enliven Therapeutics Trading Up 4.4 %

Shares of NASDAQ ELVN opened at $25.41 on Thursday. The company has a market capitalization of $1.24 billion, a P/E ratio of -13.37 and a beta of 1.08. Enliven Therapeutics, Inc. has a 12 month low of $9.80 and a 12 month high of $30.03. The stock has a 50 day moving average of $26.71 and a 200-day moving average of $24.12.

Wall Street Analyst Weigh In

ELVN has been the topic of several analyst reports. Robert W. Baird upped their price target on shares of Enliven Therapeutics from $32.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, November 15th. HC Wainwright restated a “buy” rating and set a $37.00 price objective on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.